Promoting generous support and an ethical relationship
The Canadian Hemophilia Society is committed to improve the health and quality of life of all people with inherited bleeding disorders and ultimately to find a cure.
Working together with the corporate sector in Canada helps the Canadian Hemophilia Society (CHS) accomplish its mission and vision by extending our reach and reinforcing our messages. We seek contributions from like-minded corporations which support the CHS mission and vision, and which want to participate on an annual basis in providing support to general operational, research and program development initiatives that further the work of the CHS. Contributions are accepted from corporations and from corporate foundations, employee fund programs and employee generated activities.
The National Corporate Giving Program was created with a desire to…
– be open and transparent with our members, our sponsors, other stakeholders and with the public
– publicly recognize the contributions of our sponsors to the bleeding disorder community
– treat all our sponsors fairly
– maintain the independence of our organization in representing the needs of people with bleeding disorders.
The Canadian Hemophilia Society (CHS) relies on the generosity of our donors to fulfill our mission and vision. To recognize an exceptional group of donors we have created the BeneFACTORs Club, the CHS’ highest philanthropic recognition, which symbolizes the critical bond between our organization, the donor and every person we serve with an inherited bleeding disorder. Corporations that make annual gifts of $10,000 or more to support our organization and its core programming needs are recognized as members of the BeneFACTORs Club.
Bayer is a global enterprise focused on the life science businesses of pharmaceuticals, consumer health and crop science. For more than 150 years, Bayer has been committed to creating a better life for all through science. Bayer Inc. is the Canadian subsidiary of Bayer AG and counts more than 1,360 employees across the country.
Bayer is one of the world’s main suppliers of products to treat hemophilia A. We are dedicated to helping patients with hemophilia through the advancement of recombinant factor VIII (rFVIII) therapeutic options and the development of innovative technologies, including antibody technology, gene therapy and gene editing. Together, these compounds reflect our commitment to research and development with the aim of reducing burden of treatment and improving the quality of life for people with hemophilia.
Novo Nordisk is committed to addressing the unmet needs in Hemophilia care. We work towards a future where everyone with Hemophilia is diagnosed and can live a life with as few limitations as possible. We offer a broad and innovative range of products and have a rich development pipeline to ensure we are in the forefront of finding the next generation of medicines.
Together with our partners, we work to advocate for, and create better access to, diagnosis and multidisciplinary care. We aim for better joint health and mobility including a strong focus on well-being for people living with hemophilia.
Roche – Founded in 1931, Roche Canada is committed to searching for better ways to prevent, diagnose and treat diseases while making a sustainable contribution to society. The company employs more than 1,200 people across the country through its Pharmaceuticals division in Mississauga, Ontario and our Diagnostics & Diabetes Care divisions in Laval, Quebec.
For more than 20 years, Roche has been developing medicines that redefine treatment to meet the needs of patients. Today, we are investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood.
Together with our partners in the community, we are committed to treatment options that may have a meaningful impact on how patients with hemophilia manage their disease.
Committed to hemophilia: Inspired by patients, borne from science and powered by passion
As one of the world’s largest biopharmaceutical companies, Pfizer brings its expertise and resources to help the people and families affected by hemophilia. In Canada, we have worked alongside the hemophilia community for over 23 years to create strong stakeholder collaboration. Hemophilia research is a priority within our Rare Disease Research Unit. In 2010, Pfizer solidified its commitment to rare diseases by establishing a dedicated Rare Disease team, of which hemophilia and other bleeding disorders are an area of focus. Current assets include pre-clinical and clinical programs.
– CSL Behring